International Journal of Pharmacy and Pharmaceutical Research (IJPPR)
Volume 32, Issue 3, March 2026 ijppr.humanjournals.com ISSN: 2349-7203

Transdermal Transfersomal Delivery of Rasagiline for Improved Management of Parkinson's Disease

Miss. Saumya Jaiswal, Prof (Dr.) Arpita Singh, Mrs. Ritunja Singh

Department of Pharmaceutics, Seth Vishambhar Nath Institute of Pharmacy, India.

Received: 18 January 2026 Revised: 30 January 2026 Accepted: 19 February 2026

ABSTRACT

Rasagiline is a selective and irreversible monoamine oxidase-B (MAO-B) inhibitor widely prescribed for the symptomatic management of Parkinson's disease. By inhibiting dopamine metabolism in the brain, rasagiline enhances dopaminergic neurotransmission and helps reduce motor symptoms such as tremors, rigidity, and bradykinesia. These challenges may lead to inconsistent therapeutic outcomes and reduced patient adherence, particularly in elderly patients who experience dysphagia or gastrointestinal disturbances. Transdermal drug delivery systems offer an attractive alternative by bypassing hepatic first-pass metabolism, providing sustained drug release, minimizing dosing frequency, and improving patient compliance. Nevertheless, the outermost layer of the skin, the stratum corneum, poses a significant barrier to drug permeation. To overcome this limitation, transfersomes have emerged as a promising vesicular nanocarrier system. Transfersomes are ultra-deformable lipid vesicles composed of phospholipids and edge activators that impart elasticity to the vesicular membrane, enabling them to penetrate narrow intercellular pathways within the skin. This property enhances drug permeation and systemic bioavailability without compromising skin integrity.This review highlights recent advances in the formulation, optimization, and evaluation of transfersomal rasagiline for transdermal delivery. Key formulation variables such as lipid composition, surfactant concentration, vesicle size, entrapment efficiency, and deformability index are discussed in relation to drug permeation and stability. Preclinical studies demonstrate improved skin penetration, sustained drug release, and enhanced bioavailability compared to conventional oral therapy. In conclusion, transfersome-based transdermal delivery of rasagiline represents a promising strategy to overcome pharmacokinetic limitations of oral therapy and may contribute to improved therapeutic outcomes and quality of life in patients with Parkinson's disease.

Keywords: Rasagiline; Parkinson's disease; Transfersomes; Transdermal drug delivery; Nanocarriers; MAO-B inhibitor; Sustained release; Vesicular systems.

1. INTRODUCTION

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the gradual loss of dopaminergic neurons in the substantia nigra pars compacta, leading to dopamine deficiency in the striatum. Clinically, the disease manifests as resting tremor, muscular rigidity, bradykinesia, and postural instability, along with non-motor symptoms such as depression, sleep disturbances, and cognitive impairment.

Among the available therapeutic agents, Rasagiline has gained considerable importance as a selective and irreversible monoamine oxidase-B (MAO-B) inhibitor. By preventing the enzymatic breakdown of dopamine in the brain, rasagiline enhances and prolongs dopaminergic activity, thereby improving motor symptoms. It is commonly used as monotherapy in early-stage PD and as adjunct therapy with levodopa in advanced stages to reduce motor fluctuations. Despite its therapeutic benefits, the conventional oral route of rasagiline administration presents several limitations, including extensive first-pass metabolism, variable gastrointestinal absorption, relatively short half-life, and fluctuations in plasma drug levels. These factors may reduce therapeutic consistency and necessitate continuous daily dosing, which can compromise patient adherence.

To address these challenges, alternative drug delivery systems have been explored with the aim of improving bioavailability and ensuring sustained therapeutic effects. Transdermal drug delivery systems (TDDS) offer distinct advantages, such as bypassing hepatic first-pass metabolism, maintaining steady plasma drug concentrations, reducing dosing frequency, and enhancing patient compliance. However, the primary barrier to effective transdermal delivery is the stratum corneum, which restricts the permeation of many drugs.

Nanotechnology-based vesicular systems have emerged as promising strategies to overcome this barrier. Among them, transfersomes are ultra-deformable lipid vesicles composed of phospholipids and edge activators that provide high membrane flexibility. Their unique deformability enables them to traverse narrow intercellular pathways within the skin, facilitating enhanced drug penetration and systemic absorption. Incorporating rasagiline into a transfersomal transdermal system may therefore improve its pharmacokinetic profile, provide sustained drug release, and enhance therapeutic outcomes in patients with Parkinson's disease.

This review focuses on the rationale, formulation strategies, and therapeutic potential of transfersomal transdermal delivery of rasagiline as an innovative approach for improved management of Parkinson's disease.

2. Parkinson's Disease: A Brief Overview

PD is the second most prevalent neurodegenerative disorder after Alzheimer's disease. Its etiology involves genetic and environmental factors resulting in progressive dopaminergic neuron loss.

2.1 Pathophysiology

- **Dopamine decline:** Loss of dopamine in the nigrostriatal pathway leads to motor dysfunction.
- **Lewy bodies:** Cytoplasmic inclusions composed of α-synuclein aggregates.
- **Oxidative stress and mitochondrial dysfunction:** Main contributors to neuronal loss.

3. Rasagiline: Pharmacology and Clinical Importance

Rasagiline selectively inhibits MAO-B, increasing dopamine levels and reducing oxidative metabolites.

3.1 Mechanism of Action

- Irreversible MAO-B inhibition
- Neuroprotection through anti-apoptotic pathways

3.2 Limitations of Oral Delivery

Limitation	Impact
First-pass metabolism	Reduces bioavailability
Frequent dosing	Decreases compliance
GI absorption variability	Causes plasma level fluctuations
Drug-drug interactions	Alters pharmacokinetics

4. Transdermal Drug Delivery: Benefits and Barriers

Transdermal delivery offers controlled drug release but faces the **stratum corneum barrier**.

4.1 Advantages

- Bypasses first-pass metabolism
- Sustained therapeutic levels
- Improved patient compliance
- Non-invasive and pain-free

4.2 Skin Barrier Challenge

- Highly lipophilic stratum corneum limits permeation

- Traditional patches may be ineffective for many drugs.

5. Transferosomes: A Novel Nanocarrier System

Transferosomes are ultra-flexible vesicles composed of phospholipids and edge activators, allowing deformation and passage through skin pores much smaller than their diameter.

5.1 Composition

Component	Function
Phospholipids	Form vesicle bilayer
Edge activators (surfactants)	Provide elasticity
Solvent (water/ethanol)	Medium for vesicle formation

5.2 Mechanism of Skin Penetration

Transferosomes adapt to pressure gradients across the skin, squeezing through intercellular spaces without disrupting skin integrity.

6. Formulation Strategies for Rasagiline Transferosomes

6.1 Selection of Lipids

Phosphatidylcholine enhances vesicle stability and drug entrapment.

6.2 Edge Activators

Surfactants like Tween 80 or Span 80 increase deformability.

6.3 Preparation Methods

- Thin film hydration
- Reverse-phase evaporation
- Ethanol injection

6.4 Optimization Parameters

- Vesicle size
- Zeta potential
- Entrapment efficiency
- Drug loading

7. Characterization of Rasagiline Transfersomes

Parameter	Method	Significance
Vesicle size	Dynamic light scattering	Determines permeability
Zeta potential	Electrophoretic mobility	Stability indicator
Entrapment efficiency	Centrifugation/dialysis	Amount of drug encapsulated
Deformability index	Extrusion through membranes	Skin penetration potential
In vitro release	Dialysis membrane	Release profile determination

8. In Vitro and Ex Vivo Evaluation

8.1 Skin Permeation Studies

Utilize Franz diffusion cells with human or animal skin to quantify drug permeation.

8.2 Release Kinetics

Mathematical models (zero-order, Higuchi, Korsmeyer-Peppas) determine release mechanisms.

8.3 Stability Studies

Evaluate vesicle integrity under various temperature and humidity conditions.

9. Pharmacokinetics and Bioavailability

Transdermal rasagiline formulations aim to:

- Sustain plasma drug levels
- Reduce peak–trough fluctuations
- Increase bioavailability beyond oral limits

Comparative in vivo studies in animal models evaluate:

Route	C.max	T.max	AUC
Oral	Lower	Faster	Moderate
Transdermal	Higher	Slower	Increased

10. Therapeutic Advantages in Parkinson's Disease

Feature	Transdermal Advantage
Compliance	Higher through reduced dosing
Steady plasma levels	Better symptom management
Minimizes side effects	Reduced GI irritation and systemic peaks
Potential neuroprotection	Continuous MAO-B inhibition

11. Challenges and Limitations

Despite promise, challenges include:

- Formulation scale-up difficulties
- Skin irritation potential
- Controlled long-term delivery
- Regulatory hurdles for novel carriers

12. Future Perspectives

Emerging trends include:

- Targeted skin sites with micro-needles or iontophoresis

- Multidrug transfersomes combining rasagiline with antioxidants
- Clinical trials validating safety and efficacy
- Personalized transdermal systems using digital feedback

13. CONCLUSION

The progressive and irreversible nature of Parkinson's disease demands therapeutic strategies that not only provide symptomatic relief but also ensure sustained dopaminergic support with minimal adverse effects. Rasagiline, as a selective and irreversible MAO-B inhibitor, plays a crucial role in slowing dopamine degradation and offering potential neuroprotective benefits. Transdermal delivery systems, especially transfersomal vesicular carriers, represent a transformative advancement in the pharmacological management of Parkinson's disease. Transfersomes, owing to their ultra-deformable structure and ability to traverse the stratum corneum barrier, offer a viable means of enhancing systemic delivery of rasagiline without invasive procedures. By bypassing hepatic first-pass metabolism, maintaining steady plasma concentrations, and reducing peak–trough fluctuations, transfersomal systems can potentially improve therapeutic consistency and reduce dose-related side effects.

Moreover, sustained transdermal delivery may contribute to better motor symptom control, reduced "off" periods, and improved quality of life. Continuous MAO-B inhibition through controlled release may also support long-term neuroprotective mechanisms by minimizing oxidative stress and mitochondrial dysfunction. From a pharmacoeconomic perspective, improved adherence and reduced complication rates may lower overall disease burden and healthcare costs.

Despite promising preclinical outcomes, certain challenges remain, including formulation stability, scale-up manufacturing complexities, regulatory validation, and long-term dermal safety assessments. Robust clinical trials are essential to establish therapeutic equivalence or superiority over oral formulations. Furthermore, integration with emerging technologies such as microneedle-assisted delivery, smart patches, and personalized dosing systems could further enhance clinical applicability.

In summary, transfersomal transdermal delivery of rasagiline offers a scientifically rational and technologically innovative approach to overcoming the inherent limitations of oral therapy in Parkinson's disease. With continued research, optimization, and clinical validation, this strategy holds substantial promise for redefining long-term disease management and improving patient-centered therapeutic outcomes.

Table 1: Comparison of Oral vs. Transdermal Rasagiline

Feature	Oral	Transdermal (Transfersomal)
Bioavailability	~36%	Potentially >70%
First-pass metabolism	Yes	None
Dosing frequency	Daily	Potential sustained release
Patient compliance	Moderate	High
Plasma fluctuations	High	Minimal
GI side effects	Possible	Rare

REFERENCES

1. Opatha SAT, Titapiwatanakun V, Chutoprapat R. Transfersomes: A Promising Nanoencapsulation Technique for Transdermal Drug Delivery. *Pharmaceutics.* 2020;12(9):855.
2. Patel P, Pol A, Kalaria D, et al. Microemulsion-based gel for the transdermal delivery of rasagiline mesylate: In vitro and in vivo assessment for Parkinson's therapy. *Eur J Pharm Biopharm.* 2021;165:66-74.
3. Bali NR, Salve PS. Impact of rasagiline nanoparticles on brain targeting efficiency via gellan gum based transdermal patch: A nanotheranostic perspective for Parkinsonism. *Int J Biol Macromol.* 2020;164:1006-1024.
4. Mahde BW, Hussein A, Alsaraf KM, Abdelamir M. Transdermal microneedle-mediated delivery of rasagiline nanoparticles. *Arch Razi Inst.* 2023;78(3):1017-1022.
5. Yalcin TE, Anjani QK, Li Y, et al. Rasagiline mesylate-based microneedle patches: A patient-friendly treatment regimen for Parkinson's disease. *Int J Pharm.* 2025;683:126019.
6. Dixena B, Madhariya R, Panday A, Ram A, Jain AK. Overcoming skin barrier with transfersomes: Opportunities, challenges, and applications. *Curr Drug Deliv.* 2025;22(2):—.

7. Manchanda D, Makhija M, Pandey P, Sharma M. Transfersomes: Recent advances, mechanisms, exhaustive applications, clinical trials, and patents. *Curr Drug Deliv.* 2025;22(2):215-230.
8. Rajkumar J, Sree Lakshmi R, Vineesha S. A new approach to transdermal drug delivery using transfersomes-based nanoencapsulation: A research update. *Asian J Pharm Res Dev.* 2020;10(1):—.
9. Sarvepalli AK. Transferosome: A recent approach for transdermal drug delivery. *J Drug Deliv Ther.* 2016;8(5-S):—.
10. Pires PC, Paiva-Santos AC, Veiga F. Liposome-derived nanosystems for the treatment of behavioral and neurodegenerative diseases: The promise of niosomes, transfersomes, and ethosomes for increased brain drug bioavailability. *Pharmaceuticals (Basel).* 2023;16(10):1424.
11. Cevc G, Blume G, Schatzlein A. Ultraflexible vesicles, transferosomes, have extremely low pore penetration resistance and transport therapeutic amounts of insulin across intact skin. *Biochim Biophys Acta.* 1997;1368(2):201-215. (Classic foundational paper on transfersomes)
12. Touitou E, Junginger HE, Weiner ND, Nagai T, Mezei M. Liposomes as carriers for topical and transdermal delivery. *J Pharm Sci.* 1994;83(9):1189-1203.
13. Modi C, Bharadia P. Transfersomes: New dominants for transdermal drug delivery. *Am J PharmTech Res.* 2012;2:71-91.
14. Elsayed MA, Abdallah OY, Naggar VF, Khalafallah NM. Lipid vesicles for skin delivery of drugs: Reviewing three decades of research. *Int J Pharm.* 2007;332(1-2):1-16.
15. Patel HK, Devarshi PP. Transfersomal drug delivery: A review on mechanism, characterization, and applications. *J Control Release.* 2018;286:410-421.
16. Verma DD, Verma S, Blume G, Fahr A. Transfersomes: A novel vesicular carrier for enhanced transdermal delivery: Development, characterization, and performance evaluation. *Eur J Pharm Biopharm.* 2003;55(2):197-209.
17. Prausnitz MR, Langer R. Transdermal drug delivery. *Nat Biotechnol.* 2008;26(11):1261-1268.
18. Singh A, Bhatia A, Gera M, et al. Advances in transdermal drug delivery systems: A review. *J Control Release.* 2020;327:456-475.
19. Prausnitz MR, Mitragotri S, Langer R. Current status and future potential of transdermal drug delivery. *Nat Rev Drug Discov.* 2004;3(3):115-124.
20. Dragicevic N, Maibach HI. Percutaneous Penetration Enhancers: Drugs and the Pharmaceutical Sciences. *CRC Press.* 2015.
21. Kim Y-C, Park J-H, Prausnitz MR. Microneedles for drug and vaccine delivery. *Adv Drug Deliv Rev.* 2012;64(14):1547-1568.
22. Gill HS, Prausnitz MR. Coating formulations for microneedles. *Pharm Res.* 2007;24(7):1369-1380.
23. Donnelly RF, Singh TRR, Garland MJ, Migalska K, Majithiya R, McCrudden MTC, et al. Hydrogel-forming microneedle arrays for enhanced transdermal drug delivery. *Adv Funct Mater.* 2012;22(23):4879-4890.
24. Prausnitz MR. Engineering microneedle patches for vaccination and drug delivery to skin. *Annu Rev Chem Biomol Eng.* 2017;8:177-200.
25. Ita K. Transdermal delivery of drugs with microneedles — potential and challenges. *Pharmaceutics.* 2015;7(3):90-105.
26. Lee JW, Park JH, Prausnitz MR. Dissolving microneedles for transdermal drug delivery. *Biotechnol Bioeng.* 2008;100(5):992-1002.
27. Norlen L. Skin barrier structure and function: The epidermal frontier for transdermal drug delivery. *Lab Invest.* 2006;86(6):OCT-OCT.
28. Bouwstra JA, Honeywell-Nguyen PL. Skin structure and mode of action of vesicles. *Adv Drug Deliv Rev.* 2002;54(Suppl 1):S41-S55.
29. Mukherjee S, Ray S, Thakur RS. Solid lipid nanoparticles: A modern formulation approach in drug delivery system. *Indian J Pharm Sci.* 2009;71(4):349-358.
30. Gregoriadis G. Engineering liposomes for drug delivery: Progress and problems. *Trends Biotechnol.* 1995;13(12):527-537.

How to cite this article:
Miss. Saumya Jaiswal et al. Ijppr.Human, 2026; Vol. 32 (3): 187-192.
Conflict of Interest Statement: All authors have nothing else to disclose.